[1]青春,邓候富,贾志云.放射性核素89Sr治疗骨转移癌的新进展[J].国际放射医学核医学杂志,2007,31(3):160-162.
　QING Chun,DENG Hou-fu,JIA Zhi-yun.The new advances of radionuclide 89Sr in metastatic bone cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):160-162.
点击复制

放射性核素89Sr治疗骨转移癌的新进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第3期
页码:
160-162
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The new advances of radionuclide 89Sr in metastatic bone cancer
作者:
青春;  邓候富;  贾志云
610041 成都, 四川大学华西医院核医学科
Author(s):
QING Chun;  DENG Hou-fu;  JIA Zhi-yun
Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, China
关键词:
锶放射性同位素; 骨肿瘤; 肿瘤转移
Keywords:
Strontium radioisotopes; Bone heoplasms; Neoplasms metastases
分类号:
R817.5
摘要:
乳腺癌、前列腺癌和肺癌骨转移最常见的症状是骨疼痛.在广泛性骨转移癌出现严重骨疼痛时,那些通常使用的治疗手段即止痛药物、激素、化疗和外照射治疗都不够理想,且均可出现严重副作用或治疗失败.锶放射性同位素(89Sr)治疗骨转移癌是一种新的治疗方法,也是一种安全有效的方法,较传统治疗方式而言,更能靶向定位于所有受累部位,包括骨扫描及X线片或CT,MRI难以发现的隐匿转移癌灶,选择性病灶摄取使正常组织仅受有限的辐射剂量而治疗效率增高,副作用较小.89Sr治疗骨转移癌的总有效率大于80%,其对血细胞的抑制作用轻微且是一过性的,短期内能得到恢复.89Sr加用外放疗或者化疗药物联合治疗,能够显著减轻骨疼痛、降低治疗的副作用,并可抑制病骨病灶继续发展而延长患者的生存期.
Abstract:
Bone pain from metastatic disease is the most common in cancers of the breast, prostate, and lung. Patients, with disseminated, hormone-refractory or chemo-refractory cancer suffered from persisting bone pain, can get benefet from 89Sr. Radionuclide 89Sr, a kind of new theraphy and saltly for metastatic bone cancer.Beta-emitting of 89Sr, bone-seeking radiopharmaceuticals, concentrate in painful bone lesions,including those that can not be seen by X-ray, CT or MRI. Absorbing of 89Sr by lesions selectively can diminish the radiation dose of normal tissue and highten curative effect.Multicentre observational study proved that has been effective in providing pain relief for metastatic bone cancer with a total response rate of more than 80%, and it’s side effects were generally mild. Radionuclide 89Sr together with external beam radiotheraphy or chemotheraphy can bring patients a significant improvement in pain palliation and a cytostatic effect on bone lesions, cut down the side effect and then can also prolong patients survival effectively.

参考文献/References:

1 Silberstein EB.Teletherapy and radiopharmaceuticaltherapy of painful bone metastases.Semin Nucl Med,2005,35(2):152-158.
2 Finlay IG,Mason MD,Shelley M,Radioisotopes for the palliation of metastatic bone cancer:a systematic review.Lancet Oncol,2005,6(6):392-400.
3 Kvinnsland Y,Bruland O,Moe L,et al.A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section withadigital silicon detector:application to a study of 89SrCl2 and 153 Sm-EDTMP in a dog with spontaneous osteosarcoma.Eur J Nucl Med Mol Imaging,2002,29(2):191-197.
4 Falkmer U,Jarhult J,Wersau P,et al.Systematic overview of radiation therapy effects in skeletal metastases.Acta Oncol,2003,42(5-6):620-633.
5 Deng HF,Zhang XY,Tan TZ,et al.Treatment of metastatic bone pain with Strontium-89.J Nucl Med,2003,44(5):413.
6 范义湘,罗荣成,李贵平,等.骨显像联合B-AKP测定评价89Sr治疗前列腺癌骨转移疗效.中华男科学,2004,10(3):178-181.
7 Zyskowski A,Lamb D,Morum P,et al.Stronlium-89 treatment for prostate cancer bone metastases,does a prostate-specific antigen response predict for improved survival?.Australas Radiol,2001,45(1):39-42.
8 Soerdjbalie-Maikoe V,Pelger RC,Lyckiama â Nijeholt GA,et al.Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.Eur J Nucl Med Mol Imaging,2002,29(4):494-498.
9 Oosterhof GO,Roberts JT,de Reijke TM,et al.Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer:a phase III study of the European Organisation for Research and Treatment of Cancer,Genitourinary Group.Eur Urol,2003,44(5):519-526.
10 Sciuto R,Festa A,Rea S,et al.Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.J Nucl Med,2002,43(1):79-86.
11 Pagliaro LC,Delpassand ES,Williams D,et al.A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.Cancer,2003,97(12):2988-2994.

相似文献/References:

[1]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
　Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
[2]郑玉明,程霞,郑棒.自制90Sr保持架在皮肤病敷贴治疗中的辐射防护作用[J].国际放射医学核医学杂志,2014,38(1):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
　Zheng Yuming,Cheng Xia,Zheng Bang.Effects of serf-made 90Sr applicator retainer on radiation protection in treatment of skin disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
[3]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[4]叶慧,莫逸,谢爱民,等.18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究[J].国际放射医学核医学杂志,2008,32(3):147.
　YE Hui,MO Yi,XIE Ai-min,et al.Comparison study of 18F-fluorodeoxyglucose PET-CT and 99Tc-methylene phospho-nate bone scan in detecting bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):147.
[5]郭睿,晋建华,任媛,等.99mTc-枸橼酸盐显像鉴别骨转移癌与良性退行性骨病变[J].国际放射医学核医学杂志,2008,32(3):162.
　GUO Rui,JIN Jian-hua,REN Yuan,et al.Differentiation of malignant and degenerative benign bone disease using 99mTc-citrate scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):162.
[6]王娜,刘生.全身骨显像骨外伪影的原因分析[J].国际放射医学核医学杂志,2008,32(5):301.
　WANG Na,LIU Sheng.Analysis of artifact imaging of extraosseous tissues in whole-body bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):301.
[7]耿峻,吴兴勇,胡德胜,等.前列腺癌48例患者全身核素骨显像的临床价值[J].国际放射医学核医学杂志,2007,31(4):238.
[8]陈坤山.在锝极有限情况下如何充分利用锝进行骨显像[J].国际放射医学核医学杂志,2007,31(4):239.
[9]王俊起,高硕.PET评价骨转移瘤[J].国际放射医学核医学杂志,2006,30(2):87.
　WANG Jun-qi,GAO Shuo.PET in the evaluation of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):87.
[10]袁志斌.89Sr及联合治疗转移性骨肿瘤的临床应用[J].国际放射医学核医学杂志,2005,29(2):53.
　YUAN Zhi-bin.The clinical application of strontium-89 concomitant use with other modalities in the treatment of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):53.
[11]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[12]何建华,喻文才.89SrCl2与153Sm-乙二胺四亚甲基膦酸治疗骨转移癌的对比研究[J].国际放射医学核医学杂志,2009,33(2):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
　HE Jian-hua,YU Wen-cai.Comparison of treatment with 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]

备注/Memo

备注/Memo:
收稿日期:2006-10-30。
通讯作者:邓候富,E-mail:denghfy@126.com
更新日期/Last Update: 1900-01-01